Prof. Perran Fulden Yumuk
6
reviews
18/02/2026
07/11/2025
26/08/2025
12/01/2026
03/10/2025
However, after the law on full-time work was passed, we cannot meet with Mrs. Fulden as we would like. I hope the law will be repealed, and we will be able to continue our follow-up examinations together at a private institution again.
07/04/2011
Professor Perran Fulden Yumuk is a medical oncologist with many years of academic experience. She graduated from Istanbul University Faculty of Medicine in 1990 and from 1995 to 1998 she studied in the USA — at the University of Alabama at Birmingham, where she completed a three-year fellowship in hematology/oncology.
In 1999 she received certification in medical oncology from the Turkish Ministry of Health and for many years headed the medical oncology department at Marmara University School of Medicine. Today she works in the medical oncology department at VKV American Hospital in Istanbul and is simultaneously a Visiting Professor at the Department of Medical Oncology at Koç University School of Medicine; in parallel, she runs a private practice.
Her scientific profile includes 267 publications and more than 5,400 citations. She actively participates in national multicenter studies of the Turkish Oncology Group (TOG) — on EGFR/ALK-positive lung cancer, immunotherapy (PD-L1, atezolizumab), and molecular tumor profiling.
In 2025, Professor Yumuk reconfirmed her ESMO certification — an independent European assessment of the current level of knowledge in medical oncology. Member of ESMO and ASCO.
Achievements and awards
About Professor Perran Fulden Yumuk
- lung cancer (non-small cell, EGFR/ALK-positive),
- breast cancer,
- colorectal cancer,
- gastroenteropancreatic neuroendocrine tumors,
- soft tissue sarcomas.
- 1990 — Istanbul University Faculty of Medicine, MD diploma.
- 1995 — certification in internal medicine, Turkish Ministry of Health.
- 1995–1998 — fellowship in hematology and oncology, University of Alabama at Birmingham, USA.
- 1999 — certification in medical oncology, Turkish Ministry of Health.
- 2002–2005 — instructor, Marmara University Faculty of Medicine, Department of Medical Oncology.
- From 2005 — associate professor, then professor, Marmara University.
- 2025 — successfully passed the European Society for Medical Oncology (ESMO) exam.
- 2002–2005 — instructor, Department of Internal Medicine, Division of Medical Oncology, Marmara University Faculty of Medicine.
- From 2005 — associate professor, then professor, Marmara University.
At various periods — head of the Department of Medical Oncology, Marmara University Faculty of Medicine. - Visiting Professor — Koç University Faculty of Medicine.
Current place of work — Department of Medical Oncology, VKV American Hospital, Istanbul. - Private practice — Prof. Dr. P. Fulden Yumuk private practice.
- ResearchGate — 267 publications, more than 50,500 reads, 5,426 citations.
AD Scientific Index 2025 — ranking in the field of medical oncology (world rank #356,477). - Turkish Oncology Group (TOG) — active participant; co-author of multicenter studies on non-small cell lung cancer, molecular profiling, and immunotherapy (PD-L1, atezolizumab).
- European Society for Medical Oncology (ESMO) — member; in 2025 confirmed the ESMO exam.
- American Society of Clinical Oncology (ASCO) — member.
- Marquis Who’s Who — recognized as an outstanding oncologist and educator.
VKV American Hospital — a private multidisciplinary hospital in Istanbul managed by the Vehbi Koç Foundation, with JCI accreditation. It is one of the oldest private clinics in Turkey focused on international patients, with close integration with the Koç University School of Medicine.
The medical oncology department at American Hospital specializes in the treatment of solid tumors and works closely with the MD Anderson Radiation Treatment Center, which has been operating at the same hospital since 2010 in partnership with the MD Anderson Cancer Center (Houston). This enables a multidisciplinary approach: chemotherapy and targeted therapy from medical oncologists plus radiation treatment to international standards in one institution.
For Professor Yumuk’s patients, this means access to modern systemic therapy for lung cancer, breast cancer, colorectal cancer, neuroendocrine tumors, and sarcomas; the opportunity to participate in clinical trials through the TOG network and the partnership with MD Anderson; multidisciplinary oncology councils; and an international patient department with translators and video consultations.
